ALK and non-small cell lung carcinoma: A host of genetic modifications have been found in NSCLC, such as anomalies in the epidermal growth factor receptor (EGFR) and KRAS genes or changes concerning the anaplastic lymphoma kinase (ALK) gene, leading to the advent of targeted therapeutic interventions [5].